Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2008

View Archived Issues

Reduced ventricular tachycardia, fibrillation with celivarone in ICD patients

Elite presents update on abuse-resistant pain products

Dalcetrapib safe in phase II hyperlipidemia studies

Anisodamine attenuates slow reflow phenomenon after primary PCI

Efficacy successfully shown in phase III study of binodenoson for detecting ischemia

Novartis reports results from ALLAY study of Rasilez in left ventricular hypertrophy

Nymox releases new clinical data on its prostate drug NX-1207

Can-Fite enrolls first patient in phase IIb rheumatoid arthritis trial

ThromboGenics completes patient enrollment in phase IIb MIVI III trial of microplasmin

Cell Genesys and Takeda form global alliance for GVAX immunotherapy for prostate cancer

Acadia initiates second phase III trial of pimavanserin for Parkinson's disease psychosis

Cortex initiates enrollment in clinical trial of CX-717 in opiate induced respiratory depression

Cougar reaches agreement with FDA under SPA for phase III clinical trial of CB-7630

Repros reports interim safety results from study of Proellex in uterine fibroids

Amorcyte completes phase I stem cell therapy trial for acute myocardial infarction

Pfizer discontinues phase III CP-675,206 trial in advanced melanoma

Supratek's SP-1049C granted orphan drug designation for gastric cancer

AGI presents pharmacokinetic findings from arbaclofen clinical study

Positive efficacy results reported for istaroxime in acute heart failure

Sinovac receives China's approval for pandemic influenza H5N1 vaccine

Abraxis enrolls patients in phase II study of Coroxane in vascular disease prevention

FDA grants orphan drug designation to resveratrol formulation in MELAS syndrome

Novogen cardiovascular drug enters phase I clinical trial

Recent patents report novel agents for gastrointestinal disorders

New antidepressive agents reported in recent Lundbeck and NeuroSearch patents

Novel immunosuppressant agents disclosed in recent Actelion patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...